肠道法尼醇X受体在非酒精性脂肪性肝病中的作用机制及相关靶向药物  

Mechanism of action of intestinal farnesoid X receptor in nonalcoholic fatty liver disease and related targeted drugs

作　　者：张凯玲 李良平 ZHANG Kailing;LI Liangping(Department of Gastroenterology, Sichuan Provincial People’s Hospital, Sichuan Academy of Medical Sciences, Chengdu 610072, China)

机构地区：[1]四川省医学科学院,四川省人民医院消化内科,成都610072

出　　处：《临床肝胆病杂志》2020年第5期1160-1163,共4页Journal of Clinical Hepatology

摘　　要：近年来非酒精性脂肪性肝病(NAFLD)发病率日益剧增,若患者不良生活方式无法及时调整,且临床尚缺乏有效的药物,使得NAFLD的治疗差强人意。法尼醇X受体(FXR)作为胆汁酸的主要受体,通过参与糖、脂代谢来影响NAFLD,而肠道FXR(iFXR)具有局限作用于肠道的优势,可避免全身释放所带来的副作用,在NAFLD的治疗上具有潜在的价值,但也存在一定的争议。综述了近年来iFXR在NAFLD的研究进展。The incidence rate of nonalcoholic fatty liver disease(NAFLD)is gradually increasing in recent years,and the treatment of NAFLD is unsatisfactory due to the failure in lifestyle adjustment and a lack of effective drugs.Farnesoid X receptor(FXR),as the main bile acid receptor,may affect NAFLD by participating in glucose and fat metabolism,and intestinal FXR(iFXR)acts on the intestinal tract alone and may thus avoid the side effects of systemic release.Therefore,it may have potential value in the treatment of NAFLD,but there are also certain controversies.This article reviews the research advances in the role of iFXR in NAFLD.

关 键 词：非酒精性脂肪性肝病 法尼醇X受体 胆酸类 

分 类 号：R575.5[医药卫生—消化系统]